Last reviewed · How we verify
Norbert Avril, M.D. — Portfolio Competitive Intelligence Brief
1 marketed
0 filed
0 Phase 3
0 Phase 2
0 Phase 1
Live · 30-min refresh
Portfolio leaders (marketed + Phase 3 / filed)
| Drug | Generic | Phase | Class | Target | Area | First approval |
|---|---|---|---|---|---|---|
| [Ga-68]PSMA | [Ga-68]PSMA | marketed | PET imaging agent / radiopharmaceutical | PSMA (prostate-specific membrane antigen) | Oncology |
Therapeutic area mix
- Oncology · 1
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Competitive overlap (companies sharing drug classes)
- Assistance Publique - Hôpitaux de Paris · 1 shared drug class
- HTA Co., Ltd. · 1 shared drug class
- Hackensack Meridian Health · 1 shared drug class
- Weill Medical College of Cornell University · 1 shared drug class
Subscribe to ongoing alerts
Every new pipeline event for Norbert Avril, M.D.:
- Norbert Avril, M.D. pipeline updates — RSS
- Norbert Avril, M.D. pipeline updates — Atom
- Norbert Avril, M.D. pipeline updates — JSON
Cite this brief
Drug Landscape (2026). Norbert Avril, M.D. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/norbert-avril-m-d. Accessed 2026-06-09.